*Optimal dilutions/concentrations should be determined by the researcher.
Capture : GTX635889/GTX635891, Detection: GTX100053
Not tested in other applications.
HepG2 , Conditional medium from differentiated human primary preadipocyte , human plasma
1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.66 mg/ml (Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human Apolipoprotein E. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
apolipoprotein E , AD2 , APO-E , ApoE4 , LDLCQ5 , LPG
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq]